Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
77 hedge funds and large institutions have $292M invested in Akcea Therapeutics Inc in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 29 reducing their positions, and 12 closing their positions.
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
3% more funds holding
Funds holding: 75 → 77 (+2)
14% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 29
14% less call options, than puts
Call options by funds: $2.25M | Put options by funds: $2.62M
17% less capital invested
Capital invested by funds: $354M → $292M (-$62M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$2.46M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.79M |
| 3 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$973K |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$683K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$620K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.22M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.07M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.63M |
| 4 |
Squarepoint
New York
|
-$1.23M |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$1.19M |
AKCA Hedge Fund Activity: Q1 2020 in Review
77 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q1 2020, worth a combined $292M — down 17% from $354M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AKCA positions and 12 closed out — a net gain of 2 holders — while 25 added to existing stakes and 29 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $2.46M. The largest seller was Point72 Asset Management, cutting an estimated $3.22M.
- 77 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q1 2020, up from 75 in Q4 2019.
- Funds reported $292M of Akcea Therapeutics Inc stock for Q1 2020, down 17% quarter-over-quarter.
- 14 funds opened new Akcea Therapeutics Inc positions in Q1 2020 and 12 closed out, a net change of +2 holders.
- The largest Akcea Therapeutics Inc buyer in Q1 2020 was D.E. Shaw & Co, an estimated $2.46M added.
- The largest Akcea Therapeutics Inc seller in Q1 2020 was Point72 Asset Management, an estimated $3.22M sold.
Based on aggregated 13F filings for Q1 2020.